Anna Perdrix Rosell

Anna Perdrix Rosell has a diverse work experience spanning from 2012 to 2020. In 2012, they were a Research Assistant at IRB Barcelona and a Research Intern at Oxitec Ltd. In 2013, they completed a medical exchange internship at the International Federation of Medical Students' Associations. In 2014, they were a Research Associate at Breakthrough Breast Cancer. From 2015 to 2019, they held various roles including a PhD Candidate at The Francis Crick Institute, a Research Associate at King's College London, and a Member of the Board of Advisors at Newcastle University. In 2018, they were also named a Forbes 30 Under 30. In 2020, they became the SME leader at the Royal Academy of Engineering and Co-Founder at Sixfold Bioscience.

Anna Perdrix Rosell has an extensive education history. In 2010, they completed a BsC in Biomedical Sciences from Universitat de Barcelona. From 2014 to 2015, they earned a Master of Research in Translational Cancer Medicine from King's College London. Anna then completed a Doctor of Philosophy (Ph.D.) in Cancer Research from King's College London from 2015 to 2019. In 2016 and 2017, they attended Cambridge Judge Business School to complete the Accelerate Programme in Biotech Business Development. In 2018, they attended Y Combinator. Finally, in 2020 and 2021, they earned a Master of Business Administration (MBA) from Quantic School of Business and Technology and an Executive Leadership Development from Stanford University Graduate School of Business.